Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

The oral multi-targeted tyrosine kinase inhibitor (TKI) anlotinib is effective for non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, a fraction of patients remains non-responsive, raising the need of how to identify anlotinib-responsive patients. In the present study, we ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Shi, Qin, Zhang, Lele, Wu, Jun, Lou, Yuqing, Qian, Jie, Zhang, Bo, Wang, Shuyuan, Wang, Huimin, Zhao, Xiaodong, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749025/
https://www.ncbi.nlm.nih.gov/pubmed/31572680
http://dx.doi.org/10.3389/fonc.2019.00886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749025/
https://www.ncbi.nlm.nih.gov/pubmed/31572680
http://dx.doi.org/10.3389/fonc.2019.00886

Ejemplares similares